Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell Surface Receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Cell Surface Receptor. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-003994-23 Sponsor Protocol Number: DagainstGVH Start Date*: 2021-09-09
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Role of Vitamin D in GVHD prophylaxis in patients undergoing allogeneic stem cell transplantation. Randomized single-center pilot study
    Medical condition: Treatment of acute and chronic graft versus host disease (GVHD) after allogeneic donor hematopoietic stem cell transplantation in adult patients with haematological diseases.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10068908 AGVHD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002082-38 Sponsor Protocol Number: RG_11-123 Start Date*: 2012-04-16
    Sponsor Name:University of Birmingham
    Full Title: A study of the effects of Simvastatin on neutrophil function in elderly subjects
    Medical condition: We are investigating the effects of Simvastatin 80mg on neutrophil function (using in vitro studies of neutrophil function), in healthy elderly subjects as there is evidence to suggest that Simvast...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001157-23 Sponsor Protocol Number: GO44096 Start Date*: 2023-01-03
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF THE INTRAVENOUS FIXED-DOSE COMBINATION (IV FDC) OF TIRAGOLUMAB AND ATEZOLIZUMAB IN PARTICIPANTS WITH LOCALLY A...
    Medical condition: Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) CY (Trial now transitioned) ES (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011538-93 Sponsor Protocol Number: Maraviroc –switch Start Date*: 2010-06-07
    Sponsor Name:Imperial College London
    Full Title: A prospective, randomised study to access safety, changes in platelet reactivity, plasma cardiac biomarkers and metabolic parameters over 48 weeks in HIV-1 infected subjects undergoing a switch in...
    Medical condition: HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018331-18 Sponsor Protocol Number: ML25243 Start Date*: 2010-05-12
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A 52 week, Single center, Open-label Study to Evaluate Neutrophil function and survival effects of Tocilizumab (TCZ) in Patients with Active Rheumatoid Arthritis (RA) on Background Non-biologic DMA...
    Medical condition: Adult Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005774-25 Sponsor Protocol Number: SC104 Start Date*: 2022-06-16
    Sponsor Name:SOTIO Biotech AG
    Full Title: A phase 2, open-label, single-arm, multicenter study of SOT101 in combination with pembrolizumab to evaluate the efficacy and safety in patients with selected advanced/refractory solid tumors
    Medical condition: advanced/refractory solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    24.1 100000004864 10085908 Cutaneous squamous cell carcinoma LLT
    21.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) CZ (Prematurely Ended) BE (Completed) IT (Ongoing) HU (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002123-15 Sponsor Protocol Number: GEICAM/2019-01 Start Date*: 2020-06-15
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative hi...
    Medical condition: High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002652-42 Sponsor Protocol Number: 2007IC007H Start Date*: 2007-08-14
    Sponsor Name:Royal Brompton and Harefield NHS Trsut
    Full Title: The use of clopidogrel and aprotonin in off pump coronary artery bypass grafting
    Medical condition: Bleeding after coronary artery bypass grafting
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005645 Blood loss of (NOS) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005904-13 Sponsor Protocol Number: CF101-201PS Start Date*: 2009-02-12
    Sponsor Name:Can-Fite BioPharma, Ltd.
    Full Title: A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients with Moderate-to-Severe Plaque Psoriasis
    Medical condition: Patients with Moderate-to-Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-005386-67 Sponsor Protocol Number: 20140318 Start Date*: 2017-03-27
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b an...
    Medical condition: Hepatocellular carcinoma (HCC) and metastatic liver tumors (non-HCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    21.0 100000004864 10025628 Malignant liver tumour non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002918-41 Sponsor Protocol Number: IJB-EBC-Decrescendo-2020 Start Date*: 2021-08-25
    Sponsor Name:Institut Jules Bordet
    Full Title: De-Escalation of neoadjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chem...
    Medical condition: HER2-positive, estrogen receptor (ER)-negative/progesterone receptor (PR)-negative, node-negative early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) IT (Prematurely Ended) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003468-19 Sponsor Protocol Number: ADVL0912 Start Date*: 2020-08-14
    Sponsor Name:Children’s Oncology Group
    Full Title: ADVL0912: A PHASE 1/2 STUDY OF PF02341066, AN ORAL SMALL MOLECULE INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE (ALK) AND C-MET, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID TUMORS AND ANAPLASTIC LARGE CEL...
    Medical condition: malignant solid tumors including Inflammatory myofibroblastic tumor (IMT) and anaplastic large-cell lymphoma (ALCL)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001074-30 Sponsor Protocol Number: N20MAT Start Date*: 2020-06-26
    Sponsor Name:Netherlands cancer institute (NKI) Antioni van Leeuwenhoek (AvL)
    Full Title: Neo-adjuvant nivolumab or nivolumab with ipilimumab in advanced cutaneous squamous cell carcinoma patients prior to standard of care surgery; the MATISSE trial
    Medical condition: Primary or recurrent stage III-IVA cutaneous squamous cell carcinoma of all body sites OR tage I-II cutaneous squamous cell carcinoma, only in the case of: • Presence of multifocal disease for wh...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041834 Squamous cell carcinoma of skin PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077314 Skin squamous cell carcinoma metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081136 Skin squamous cell carcinoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004333-34 Sponsor Protocol Number: EORTC 55041 Start Date*: 2005-09-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: A randomized, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I an...
    Medical condition: Histologically confirmed high-risk FIGO stage I (grade 3, or aneuploid grade 1 or 2, or clear cell), or Stages II-IV ovarian epithelial, primary peritoneal, and fallopian tube cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10033283 HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) IT (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002488-91 Sponsor Protocol Number: MO39874 Start Date*: 2019-11-04
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) PLUS NAB-PACLITAXEL IN THE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC PD-L1-POSITIVE TRIPLE-NEGATI...
    Medical condition: Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Ongoing) SI (Ongoing) FR (Ongoing) HU (Ongoing) SK (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001237-83 Sponsor Protocol Number: BO29389 Start Date*: 2014-12-01
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF TRASTUZUMAB EMTANSINE IN PATIENTS WITH HER2 IHC-POSITIVE, LOCALLY ADVANCED OR METASTATIC NON−SMALL CELL LUNG CANCER WHO HAVE RECEIVED AT LEAST ONE PRIOR...
    Medical condition: HER2 IHC-Positive (IHC 2 + or IHC 3 +), Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000764-29 Sponsor Protocol Number: D933LC00001 Start Date*: 2018-11-29
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapi...
    Medical condition: First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epide...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004024-29 Sponsor Protocol Number: MO39196 Start Date*: 2017-06-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS ...
    Medical condition: Triple Negative Breast Cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) GR (Completed) FR (Ongoing) ES (Ongoing) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001975-40 Sponsor Protocol Number: 1219.5 Start Date*: 2007-01-04
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of a 4-week treatment of 15 mg b.i.d BIBW 2948 BS (inhalation powder, hard capsule for HandiHaler®) on e...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD) patients with symptoms associated with chronic bronchitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002245-29 Sponsor Protocol Number: BB2121-MM-001 Start Date*: 2018-10-02
    Sponsor Name:Celgene Corporation
    Full Title: A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma
    Medical condition: Relapsed and Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10067095 Multiple myeloma progression LLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA